^
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
Sci Rep - 4 days
|
trastuzumab Sensitive: A1 - Approval
Sci Rep - 4 days
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
Clin Cancer Res - 5 days
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
Clin Cancer Res - 5 days
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
neratinib Sensitive: C3 – Early Trials
Clin Cancer Res - 5 days
|
neratinib Sensitive: C3 – Early Trials
Clin Cancer Res - 5 days
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
PF-05212384 Sensitive: B - Late Trials
BioSpace - 6 days
|
PF-05212384 Sensitive: B - Late Trials
BioSpace - 6 days
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
Cancer Res Treat - 1 week
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
Cancer Res Treat - 1 week
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 1 week
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 1 week
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib + GZ17-6.02 Sensitive: D – Preclinical
Oncotarget - 1 week
|
palbociclib + GZ17-6.02 Sensitive: D – Preclinical
Oncotarget - 1 week
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
selinexor + chidamide Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
|
selinexor + chidamide Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
selinexor Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
|
selinexor Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
chidamide Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
|
chidamide Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TCHP Sensitive: A2 - Guideline
Cancer Res Treat - 2 weeks
|
TCHP Sensitive: A2 - Guideline
Cancer Res Treat - 2 weeks
|
AR positive + ER positive
|
HER2 Negative Breast Cancer
|
AR positive + ER positive
|
HER2 Negative Breast Cancer
|
enobosarm Sensitive: B - Late Trials
Veru Press Release - 2 weeks
|
enobosarm Sensitive: B - Late Trials
Veru Press Release - 2 weeks
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A1 - Approval
- 2 weeks
|
palbociclib Sensitive: A1 - Approval
- 2 weeks
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A2 - Guideline
BMC Cancer - 2 weeks
|
trastuzumab Sensitive: A2 - Guideline
BMC Cancer - 2 weeks
|
SOX2 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
SOX2 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
Pharmacol Rep - 2 weeks
|
tamoxifen Resistant: C3 – Early Trials
Pharmacol Rep - 2 weeks
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
BMC Cancer - 3 weeks
|
eribulin mesylate Sensitive: A2 - Guideline
BMC Cancer - 3 weeks
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pyrotinib Sensitive: B - Late Trials
Anticancer Drugs - 3 weeks
|
pyrotinib Sensitive: B - Late Trials
Anticancer Drugs - 3 weeks
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
CB-228 Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 weeks
|
CB-228 Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 weeks
|
LDH-H
|
HER2 Positive Breast Cancer
|
LDH-H
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
BMC Cancer - 3 weeks
|
ado-trastuzumab emtansine Resistant: C3 – Early Trials
BMC Cancer - 3 weeks
|
PTEN Hypermethylation
|
Hormone Receptor Positive Breast Cancer
|
PTEN Hypermethylation
|
Hormone Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
|
tamoxifen Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
|
PTEN underexpression
|
Hormone Receptor Positive Breast Cancer
|
PTEN underexpression
|
Hormone Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
|
tamoxifen Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
|
CDYL2 overexpression
|
HER2 Positive Breast Cancer
|
CDYL2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
Mol Cancer - 3 weeks
|
trastuzumab Resistant: C3 – Early Trials
Mol Cancer - 3 weeks
|
CDH1 deletion
|
Breast Cancer
|
CDH1 deletion
|
Breast Cancer
|
vorinostat Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
vorinostat Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
CDH1 deletion
|
Breast Cancer
|
CDH1 deletion
|
Breast Cancer
|
MGCD0103 Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
MGCD0103 Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
CDH1 deletion
|
Breast Cancer
|
CDH1 deletion
|
Breast Cancer
|
SB939 Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
SB939 Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
CDH1 deletion
|
Breast Cancer
|
CDH1 deletion
|
Breast Cancer
|
SNDX-275 Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
SNDX-275 Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
|
CDYL2 overexpression
|
HER2 Positive Breast Cancer
|
CDYL2 overexpression
|
HER2 Positive Breast Cancer
|
FAK inhibitor Sensitive: D – Preclinical
Mol Cancer - 3 weeks
|
FAK inhibitor Sensitive: D – Preclinical
Mol Cancer - 3 weeks
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + tucatinib Sensitive: A1 - Approval
|
trastuzumab + tucatinib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
margetuximab Sensitive: A1 - Approval
|
margetuximab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
TAC Sensitive: A1 - Approval
|
TAC Sensitive: A1 - Approval
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
|
pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A1 - Approval
|
alpelisib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A1 - Approval
|
abemaciclib Sensitive: A1 - Approval
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
toremifene Resistant: A1 - Approval
|
toremifene Resistant: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
albumin-bound paclitaxel Sensitive: A1 - Approval
|
albumin-bound paclitaxel Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel Sensitive: A1 - Approval
|
docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + capecitabine Sensitive: A1 - Approval
|
docetaxel + capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
HR positive
|
HER2 Positive Breast Cancer
|
HR positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
eribulin mesylate Sensitive: A1 - Approval
|
eribulin mesylate Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
non-pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
non-pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
|
trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
ixabepilone Sensitive: A1 - Approval
|
ixabepilone Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
leuprorelin depot Sensitive: A1 - Approval
|
leuprorelin depot Sensitive: A1 - Approval
|
HER-2 overexpression
|
Breast Cancer
|
HER-2 overexpression
|
Breast Cancer
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
trastuzumab + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
HER-2 overexpression
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
